Nan Fung Group Holdings Ltd
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 13, 2024), Nan Fung Group Holdings Ltd reported 44 stock positions worth $93.7 million. Its top holding was Illumina (ILMN) at 13.3% of the portfolio, followed by Harmony Biosciences (HRMY, 11.9%) and Merus (MRUS, 7.6%). Compared with Q1 2024, it opened 2 new positions, sold out of 4, added to 5 and reduced 1. The biggest buy was Merus (MRUS, shares +34%) and the biggest sale an exit from Alpine Immune Sciences (ALPN).
- Most Recent 13F
- Q2 2026
- Location
- KAI TAK, K3
- CIK
- 0001782539
- Portfolio Value
- $93.7M (Q2 2024)
- SEC Filing
- 0001012975-24-000323 ↗ filed Aug 13, 2024
Holdings Value
Holdings 44 stocks · $93.7M
| ILMN Illumina Inc. | 13.27% | 119,196 | $12.4M | No change |
| HRMY Harmony Biosciences Holdings | 11.87% | 368,665 | $11.1M | No change |
| MRUS Merus NV | 7.58% | 120,038 | $7.1M | Add +34.1% |
| GERN Geron Corp. | 6.21% | 1,373,550 | $5.8M | Add +3.7% |
| OCS Oculis Holding AG | 5.56% | 436,378 | $5.2M | No change |
| INCY Incyte Corp. | 4.79% | 74,022 | $4.5M | No change |
| EXAI Exscientia Ltd. | 4.68% | 859,892 | $4.4M | No change |
| XENE Xenon Pharmaceuticals Inc. | 4.44% | 106,680 | $4.2M | No change |
| LBPH Longboard Pharmaceuticals Inc. | 4.17% | 144,570 | $3.9M | Add +22.3% |
| MIRM Mirum Pharmaceuticals Inc. | 3.87% | 106,100 | $3.6M | Add +10.4% |
| LAB Standard Biotools Inc. | 3.56% | 1,883,179 | $3.3M | No change |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 3.50% | 23,022 | $3.3M | No change |
| KALV Kalvista Pharmaceuticals Inc. | 2.76% | 219,277 | $2.6M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 2.15% | 49,120 | $2.0M | No change |
| TRML Tourmaline Bio Inc. | 2.01% | 146,800 | $1.9M | Add +599.5% |
| RANI Rani Therapeutics Holdings Class A | 2.00% | 493,584 | $1.9M | No change |
| ASND Ascendis Pharma A/S | 1.98% | 13,600 | $1.9M | No change |
| REPL Replimune Group Inc. | 1.97% | 204,939 | $1.8M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 1.79% | 102,984 | $1.7M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 1.70% | 5,682 | $1.6M | No change |
| EXEL Exelixis Inc. | 1.54% | 64,200 | $1.4M | No change |
| ZLAB Zai Lab Ltd.-ADR | 1.02% | 55,000 | $953K | New |
| BMRN Biomarin Pharmaceutical Inc. | 0.95% | 10,815 | $890K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.93% | 1,166,952 | $875K | No change |
| TRDA Entrada Therapeutics Inc. | 0.75% | 49,082 | $699K | No change |
| ATHIRA PHARMA INC | 0.51% | 180,000 | $477K | No change |
| PACB Pacific Biosciences of Calif | 0.40% | 274,488 | $376K | No change |
| CABA Cabaletta Bio Inc. | 0.38% | 47,150 | $353K | No change |
| BCYC Bicycle Therapeutics PLC-ADR | 0.37% | 17,300 | $350K | New |
| ROIV Roivant Sciences Ltd. | 0.37% | 32,470 | $343K | No change |
| KYMR Kymera Therapeutics Inc. | 0.35% | 10,875 | $325K | No change |
| GRAL Grail Inc. | 0.33% | 19,866 | $305K | Reduce -0.2% |
| RVMD Revolution Medicines Inc. | 0.30% | 7,300 | $283K | No change |
| SWTX Springworks Therapeutics Inc. | 0.30% | 7,450 | $281K | No change |
| ALXO Alx Oncology Holdings Inc. | 0.27% | 41,950 | $253K | No change |
| IMCR Immunocore Holdings PLC-ADR | 0.24% | 6,750 | $229K | No change |
| AFMDQ Affimed NV | 0.22% | 37,247 | $203K | No change |
| IMTX Immatics NV | 0.19% | 15,700 | $182K | No change |
| BMEA Biomea Fusion Inc. | 0.19% | 40,000 | $180K | No change |
| ABCL Abcellera Biologics Inc. | 0.16% | 50,971 | $151K | No change |
| DBV TECHNOLOGIES S A | 0.16% | 185,475 | $149K | No change |
| AEROVATE THERAPEUTICS INC | 0.08% | 47,936 | $80K | No change |
| KOD Kodiak Sciences Inc. | 0.08% | 31,922 | $75K | No change |
| FIBROGEN INC | 0.06% | 62,106 | $55K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −9.69 |
| NMRA Neumora Therapeutics Inc. | Sold out | 0.00% | −0.81 |
| BCRX Biocryst Pharmaceuticals Inc. | Sold out | 0.00% | −0.17 |
| GALERA THERAPEUTICS INC | Sold out | 0.00% | −0.08 |
| GRAL Grail Inc. | Reduce -0.2% | 0.33% | +0.04 |
Portfolio Buys Q1 2024 → Q2 2024
| MRUS Merus NV | Add +34.1% | 7.58% | +3.84 |
| GERN Geron Corp. | Add +3.7% | 6.21% | +2.16 |
| LBPH Longboard Pharmaceuticals Inc. | Add +22.3% | 4.17% | +1.80 |
| MIRM Mirum Pharmaceuticals Inc. | Add +10.4% | 3.87% | +1.63 |
| TRML Tourmaline Bio Inc. | Add +599.5% | 2.01% | +1.57 |
| ZLAB Zai Lab Ltd.-ADR | New | 1.02% | +1.02 |
| BCYC Bicycle Therapeutics PLC-ADR | New | 0.37% | +0.37 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $131.5M | MPLT, LBRX, EVMN, HELP, INCY |
| Q1 2026 | 24 | $121.3M | EVMN, MPLT, LBRX, OCS, INCY |
| Q4 2025 | 27 | $111.7M | EVMN, MPLT, OCS, MDGL, LBRX |
| Q3 2025 | 24 | $59.6M | OCS, MDGL, ONC, INCY, RYTM |
| Q2 2025 | 20 | $63.4M | HRMY, ILMN, OCS, INCY, ONC |
| Q1 2025 | 35 | $122.6M | HRMY, OCS, ILMN, VRNA, ZLAB |
| Q4 2024 | 35 | $116.9M | ILMN, HRMY, OCS, VRNA, ZLAB |
| Q3 2024 | 38 | $116.1M | ILMN, HRMY, GERN, MRUS, ZLAB |
| Q2 2024 | 44 | $93.7M | ILMN, HRMY, MRUS, GERN, OCS |
| Q1 2024 | 45 | $107.9M | ILMN, HRMY, ALPN, OCS, LAB |